Skip to main content
. 2021 Oct 6;4(2):e30473. doi: 10.2196/30473

Table 2.

Study population outcomes.

Characteristic Overall cohorta (n=114) Phase 2b (n=33) Phase 3c (n=45) Phase 4d (n=36) P value
Operating time (min), median (IQR) 338 (240-489) 248 (178-379) 285 (228-353) 350 (259-456) .01
Blood transfusion (yes), n (%) 20 (17.5) 5 (15.2) 6 (13.3) 9 (25.0) .36
Length of hospital stay (days), median (IQR) 6 (5-11.8) 6 (4-8) 6 (5-8) 6.5 (4-17) .79
Pain score, mean (SD)

PODe 1 2.7 (1.0) 2.7 (0.7) 2.7 (1.0) 2.7 (1.5) .98

POD 2 1.8 (1.5) 2.3 (1.8) 1.8 (1.2) 1.3 (1.3) .01
Ambulated ≥30 m on POD 2 (yes), n (%) 93 (81.6) 24 (72.7) 40 (88.9) 29 (80.6) .19

Actual distance walked (m), median (IQR) 50 (30-100) 40 (21-100) 70 (45-100) 50 (30-100) .16
Reasons for failing to achieve target ambulation (n=21), n (%) .51

Pain 6 (28.6) 2 (22.2) 2 (40.0) 2 (28.6)

Lethargy/giddiness 5 (23.8) 3 (33.3) 1 (20.0) 1 (14.3)

Nausea 2 (9.5) 1 (11.1) 1 (20.0) 0 (0)

Hypotension/tachycardia 2 (9.5) 1 (11.1) 0 (0) 1 (14.3)

Medical instructions (postchest tube removal) 2 (9.5) 2 (22.2) 0 (0) 0 (0)

Local protocols (ongoing blood transfusion) 2 (9.5) 0 (0) 1 (20.0) 1 (14.3)

Admitted to ICUf 2 (9.5) 0 (0) 0 (0) 2 (28.6)
Morbidity, n (%)

Falls 0 (0) 0 (0) 0 (0) 0 (0) N/Ag

Pneumonia 6 (5.3) 2 (6.1) 1 (2.2) 3 (8.3) .46

Deep vein thrombosis 0 (0) 0 (0) 0 (0) 0 (0) N/A

aOverall cohort refers to the study population from phases 2 to 4. Study demographics are not shown for phase 1 patients.

bPhase 2 refers to the period during CPIP implementation (May 2019 to September 2019).

cPhase 3 refers to the sustainability phase post-CPIP but before the COVID-19 pandemic (October 2019 to March 2020).

dPhase 4 refers to the sustainability phase post-CPIP during the COVID-19 pandemic (April 2020 to September 2020).

ePOD: postoperative day.

fICU: intensive care unit.

gN/A: not applicable.